ACP
IDYA icon

Acuta Capital Partners’s IDEAYA Biosciences IDYA Stock Holding History

Acuta Capital Partners’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-350
Closed -$1.17M – 24
2026
Q1 		$1.17M Buy
+350
New +$11.7K 0.82% 22

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Acuta Capital Partners's IDYA Position: Q2 2026 in Review

Acuta Capital Partners sold out of IDEAYA Biosciences (IDYA) in Q2 2026, closing a stake of 48,234 shares — an estimated $1.61M sold.

Acuta Capital Partners first reported a position in IDYA in Q3 2022 and held it in 2 quarters. The position peaked at $1.61M in Q1 2026. 284 funds tracked by Wall St. Rank hold IDYA as of Q2 2026.

  • Acuta Capital Partners reported no remaining IDEAYA Biosciences position as of Q2 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 48,234 IDEAYA Biosciences shares in Q2 2026, an estimated $1.61M.
  • Acuta Capital Partners first reported a position in IDEAYA Biosciences in Q3 2022 and held it in 2 quarters.
  • Acuta Capital Partners's IDEAYA Biosciences position peaked at $1.61M in Q1 2026.
  • 284 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.